Source: Eur Respir J, 51 (3) 1702480; 10.1183/13993003.02480-2017
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Tiziana Masini, Janika Hauser, Rutendo Kuwana, Nguyen Nhat Linh, Ernesto Jaramillo. Will regulatory issues continue to be a major barrier to access to bedaquiline and delamanid?. Eur Respir J, 51 (3) 1702480; 10.1183/13993003.02480-2017

Member's Comments

No comment yet.

Related content which might interest you: The sustainability agenda and inhaled therapy: what do patients want? Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Pros: governments should impose targets for healthcare professionals to switch their respiratory disease patients to inhalers with a low global warming potential Source: International Congress 2019 – Recent clinical advances in inhalation therapy Year: 2019 Getting the rehabilitation message across: emerging barriers and positive health benefits Source: Eur Respir J 2009; 34: 2-4 Year: 2009 Clinical use of new and repurposed drugs: the role and contribution of the ERS collaborative projects Source: International Congress 2017 – In the frontline of the fight against tuberculosis Year: 2017 Cons - governments should impose targets for healthcare professionals to switch their respiratory disease patients to inhalers with a low global warming potential Source: International Congress 2019 – Recent clinical advances in inhalation therapy Year: 2019 Do we need new antibiotics? Source: Annual Congress 2009 - Antibiotics and the lung Year: 2009 Getting approval for new therapeutic medical devices versus drugs: are the differences justified? Source: Eur Respir Rev 2016; 25: 223-226 Year: 2016 The issues and the controversies: are we really ready for on-demand use of ICS? Source: Annual Congress 2013 –Inhaled corticosteroids for asthma: on-demand or continuous use? Year: 2013 The effect of respiratory comorbidities on the provision of cessation assistance in six EU countries: are clinicians doing enough? Source: International Congress 2018 – EUREST-PLUS: implementation of the tobacco control policy to reduce lung disease Year: 2018 Preventing skin care issues associated with face masks used for domiciliary non-invasive ventilation: what do users and their carers think are the most relevant future research questions? Source: International Congress 2019 – Treatment of chronic respiratory failure with noninvasive ventilation Year: 2019 What are the knowledge gaps in COPD that prevent new drug development? Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 MDR-/XDR-TB: what are the unresolved problems in the clinical management? Source: Annual Congress 2012 - PG7 TB and MDR-/XDR-TB: what is new in diagnosis, treatment and follow-up (TB PAN-NET) Year: 2012 Do users want to be involved in respiratory service development? Source: Eur Respir J 2004; 24: Suppl. 48, 66s Year: 2004 Crowdfunding for respiratory research: a new frontier for patient and public engagement? Source: Eur Respir J, 50 (4) 1701333; 10.1183/13993003.01333-2017 Year: 2017 The benefits and challenges of involving patients as project partners: the professional perspective Source: International Congress 2015 – Involve patients in research projects Year: 2015 Who can pay for innovative medicines? Source: Eur Respir J 2013; 41: 495-496 Year: 2013 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Strategies to effectively communicate science to patients and the wider public Source: International Congress 2019 – Effective communication of scientific findings Year: 2019